Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic-Myeloproliferative Diseases 1

Interventions

Specimen Handling 5Biopsy 5Whole-Body Irradiation 3Mycophenolic Acid 3Cyclosporine 3Cyclophosphamide 3Azacitidine 3venetoclax 2ruxolitinib 2fludarabine phosphate 2decitabine and cedazuridine drug combination 2Sirolimus 2Melphalan 2Injections 2Granulocyte Colony-Stimulating Factor 2Decitabine 2Busulfan 2veliparib 1tocilizumab 1tagraxofusp 1posaconazole 1peginterferon alfa-2b 1iadademstat 1gilteritinib 1fludarabine 1fedratinib 1axatilimab 1Tranexamic Acid 1Topotecan 1Tacrolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic-Myeloproliferative Diseases × posaconazole × 90 days × Clear all
NCT04771130 2026-04-23

A Study of BGB-11417 in Participants With Myeloid Malignancies

BeOne Medicines

Phase 1/2 Recruiting
260 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡